MetaMedical™ Solutions Inc

DURECT sees highest filings and grants during August in Q3 2023

DURECT has been focused on protecting inventions in Japan(JP) with 4 publications in Q3 2023

The Japan(JP) Patent Office dominates the patent filings and grants with nearly 40% filings and 0% grants. The Japan(JP), United States(US), China(CN), and South Korea(KR) patent Office are among the top ten patent offices where DURECT is filings its patents. Among the top granted patent authorities, DURECT has 33% of its grants in China(CN), 33% in South Korea(KR), and 33% in Canada(CA).

Johnson & Johnson could be the strongest competitor for DURECT

Johnson & Johnson and Sanofi secured the top positions according to recent patent publication data.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free

Your download email will arrive shortly

We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

Patents related to rare diseases and lead DURECT’s portfolio

DURECT has the highest number of patents in rare diseases followed by, and . For rare diseases, nearly 100% of patents were filed and 0% of patents were granted in Q3 2023.

Leiomyosarcoma related patents lead DURECT portfolio followed by hodgkin lymphoma (b-cell hodgkin lymphoma), and alcohol addiction

DURECT has highest number of patents in leiomyosarcoma followed by hodgkin lymphoma (b-cell hodgkin lymphoma), alcohol addiction, pancreatic ductal adenocarcinoma and colorectal tumor. For leiomyosarcoma, nearly 2% of patents were filed and 0% of patents were granted in Q3 2023.

For comprehensive analysis of DURECT’s filings and grants, buy the databook here.

Source link